25.05.2017 • NewsElaine BurridgeCompetitionRemicade

UK Watchdog Accuses Merck of Breaking Competition Law

(c) David Smart/Shutterstock
(c) David Smart/Shutterstock

The UK’s Competition and Markets Authority (CMA) has provisionally ruled that a discount scheme operated by US drugmaker Merck for Remicade may have broken competition rules by restricting competition from cheaper biosimilar versions.

Following an investigation that started in December 2015, the watchdog said it believes the company abused its dominant position, although stressed that findings are provisional and it will carefully consider any representations by the company.

Remicade (infliximab) is a top seller for Merck, generating annual revenues of more than $10 billion. The drug is used mainly to treat patients with gastroenterology and rheumatology conditions such as Crohn’s disease, ulcerative colitis and rheumatoid arthritis. Cheaper versions of the drug entered the European market in February 2015 when the patent expired.

Merck Sharp & Dohme (MSD), the international arm of US Merck, said it is confident proceedings will show it has complied with competition law at all times. “The discounts in question meant that infliximab was competitively priced and offered savings to the UK National Health Service, without hindering competition,” the company stated. CMA said it proposed to find MSD and parent Merck “jointly and severally liable” for the alleged infringement.

According to media reports, MSD announced in October 2015 that it would offer the NHS discounts amounting to £48 million on sales of £191 million after the National Institute for Health and Clinical Excellence (NICE) approved both Remicade and biosimilar versions.

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.